The American Journal of Medicine, Journal Year: 2024, Volume and Issue: 137(12), P. 1168 - 1169
Published: Aug. 13, 2024
Language: Английский
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 25, 2024
Circulating tumor cells (CTCs), circulating DNA (ctDNA), and extracellular vehicles (EVs) have received significant attention in recent times as emerging biomarkers subjects of transformational studies. The three main branches liquid biopsy evolved from the primary detection targets—CTC, ctDNA, EVs—each with distinct benefits. CTCs are derived cancer original or metastases may display global features tumor. ctDNA has been extensively analyzed used to aid diagnosis, treatment, prognosis neoplastic diseases. EVs contain tumor-derived material such DNA, RNA, proteins, lipids, sugar structures, metabolites. provide different contents but strong complementarity a certain extent. Even though they already employed several clinical trials, utility is still being studied, promising initial findings. This review thoroughly overviews established technologies for isolation, characterization, content CTC, EVs. Also discussed were most developments study potential therapeutic monitoring, prediction. These included Finally, challenges employing based on precision medicine evaluated.
Language: Английский
Citations
30
International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 29(5), P. 495 - 511
Published: March 29, 2024
Circulating tumor DNA (ctDNA) is the fraction of cell-free in patient blood that originates from a tumor. Advances sequencing technologies and our understanding molecular biology tumors have increased interest exploiting ctDNA to facilitate detection residual disease (MRD). Analysis as promising MRD biomarker solid malignancies has central role precision medicine initiatives exemplified by CIRCULATE-Japan project involving patients with resectable colorectal cancer. Notably, underscores prognostic significance status at 4 weeks post-surgery its correlation adjuvant therapy efficacy interim analysis. This substantiates hypothesis critical indicator relapse Despite remarkable advancements, challenges endure, primarily attributable exceedingly low concentration peripheral blood, particularly scenarios shedding intrinsic error rates current technologies. These complications necessitate more sensitive sophisticated assays verify clinical utility across all tumors. Whole genome (WGS)-based tumor-informed recently demonstrated ability detect parts-per-million range. review delineates landscape assays, highlighting WGS-based approaches forefront technique Additionally, it introduces upcoming endeavor, pan-cancer via ctDNA, forthcoming project, SCRUM-Japan MONSTAR-SCREEN-3.
Language: Английский
Citations
9
Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15
Published: July 9, 2024
Fundamentally precision oncology illustrates the path in which molecular profiling of tumors can illuminate their biological behavior, diversity, and likely outcomes by identifying distinct genetic mutations, protein levels, other biomarkers that underpin cancer progression. Next-generation sequencing became an indispensable diagnostic tool for diagnosis treatment guidance current clinical practice. Nowadays, tissue analysis benefits from further support through methods like comprehensive genomic liquid biopsies. However, medicine field presents specific hurdles, such as cost-benefit balance widespread accessibility, particularly countries with low- middle-income. A key issue is how to effectively extend next-generation all patients, thus empowering decision-making. Concerns also quality preservation samples, well evaluation health technologies. Moreover, technology advances, novel assessments are being developed, including study Fragmentomics. Therefore, our objective was delineate primary uses sequencing, discussing its’ applications, limitations, prospective paths forward Oncology.
Language: Английский
Citations
6
Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 203, P. 104483 - 104483
Published: Aug. 17, 2024
Language: Английский
Citations
5
Thoracic Cancer, Journal Year: 2025, Volume and Issue: 16(4)
Published: Feb. 1, 2025
ABSTRACT Objective To explore the clinical value of molecular residual disease detection based on circulating tumor DNA (ctDNA‐MRD) in perioperative period esophageal squamous cell carcinoma (ESCC) and to analyze escape mechanisms MRD‐positive cases. Methods A total 35 ESCC patients were prospectively enrolled. Preoperative postoperative (1 month after surgery) blood surgical tissue samples analyzed. ctDNA variants tracked plasma assess ctDNA‐MRD, whole‐transcriptome sequencing was performed MRD‐negative samples. Results positive 54.3% patients, with a 31.6% predictive for recurrence. One postsurgery, rate 17.1%, an 83.3% Both preoperative positivity significant prognostic indicators (HR = 2.78, p < 0.05; HR 4.42, 0.001). Multivariate analysis confirmed as independent factor 303.75, Transcriptomic revealed increased macrophage (W 15 848; 0.01) follicular helper T (Tfh) 10 935; levels suggesting potential link immune tumors. Conclusions Plasma measured 1 postoperatively can effectively detect MRD, ctDNA‐MRD serves risk The mechanism underlying MRD may involve polarization Tfh cells macrophages, aiding through bloodstream.
Language: Английский
Citations
0
Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: April 1, 2025
In the practice of colorectal cancer (CRC), traditional tumor tissue analysis is limited by intratumoral and intertumoral heterogeneity its invasive nature. Circulating DNA (ctDNA) analysis, a promising liquid biopsy approach, has been increasingly explored in clinical studies. Biologically, ctDNA characterized tumor-specific diversity rapid clearance from circulation, enabling real-time, dynamic, repeatable assessments. Technologically, PCR- NGS-based downstream methods have developed validated. However, variables pre-analytical analytical procedures underscores need for standardized protocols. Compared with clinicopathology-based risk stratification, ctDNA-based molecular residual disease detection demonstrated significant potential guiding treatment decisions. Qualitative quantitative changes also shown predictive prognostic value during neoadjuvant or adjuvant treatment, as well later-line metastatic CRC. Specific aberrations can not only assist identifying candidates targeted therapies but reveal resistance mechanisms. Additionally, emerging research exploring early detection. Overall, novel biomarker, holds substantial promise advancing practice. This review focuses on biological characteristics, variables, summarizes role across various scenarios
Language: Английский
Citations
0
Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: April 20, 2025
Next-generation sequencing (NGS) has emerged as a pivotal technology in the field of oncology, transforming approach to cancer diagnosis and treatment. This paper provides comprehensive overview integration NGS into clinical settings, emphasizing its significant contributions precision medicine. enables detailed genomic profiling tumors, identifying genetic alterations that drive progression facilitating personalized treatment plans targeting specific mutations, thereby improving patient outcomes. capability facilitates development leading improved outcomes potential for better prognosis. The application extends beyond actionable mutations; it is instrumental detecting hereditary syndromes, thus aiding early preventive strategies. Furthermore, plays crucial role monitoring minimal residual disease, offering sensitive method detect recurrence at an stage. Its use guiding immunotherapy by biomarkers predict response also highlighted. Ethical issues related testing, such concerns around consent data privacy, are important considerations need be addressed broader implementation NGS. These include complexities interpretation, robust bioinformatics support, cost considerations, ethical testing. Addressing these challenges essential widespread adoption Looking forward, advancements single-cell liquid biopsies promise further enhance diagnostics review emphasizes transformative impact oncology advocates incorporation routine practice promote molecularly driven care.
Language: Английский
Citations
0
Clinical Lymphoma Myeloma & Leukemia, Journal Year: 2025, Volume and Issue: unknown
Published: May 1, 2025
Language: Английский
Citations
0
Thyroid, Journal Year: 2025, Volume and Issue: 35(5), P. 462 - 470
Published: May 1, 2025
Background: Anaplastic thyroid cancer (ATC) is an aggressive that leads to rapid death if left untreated. However, recent advances in ATC treatment have dramatically changed the prognosis a select group of patients with BRAFV600E mutations. In these patients, BRAF/MEK inhibitors been shown and rapidly shrink tumors. Yet, responses are short-lived unless additional modalities applied. without mutation, current available therapies far less effective. Summary: this article, we review relevant literature propose applying "Total Therapy" approach used since 1960s for another deadly but curable disease, acute lymphocytic leukemia, ATC. We adapted concepts Induction, Consolidation, Maintenance, them This regimen integrates treatments found be successful ATC: combination systemic therapy using targeted plus immunotherapy, surgery, radiation, continuation several years, thereby attempting eradicate all residual cells. Conclusions: There has renewed interest understanding genomics treating urgency rather than just providing palliative care. shift led significant improvements With right tools clear roadmap guide us, now aim take on challenge curing patients.
Language: Английский
Citations
0
American Society of Clinical Oncology Educational Book, Journal Year: 2025, Volume and Issue: 45(3)
Published: May 20, 2025
Muscle-invasive bladder cancer (MIBC) is an aggressive disease, with substantial recurrence risk after radical cystectomy and pelvic lymph node dissection alone. In cisplatin-eligible patients, administration of neoadjuvant cisplatin-based chemotherapy followed by has been shown to improve overall survival (OS) become the standard care. Nevertheless, approximately 40%-50% patients will still experience disease curative-intent treatment. Moreover, a significant proportion MIBC are ineligible for cisplatin represent challenging clinical scenario. recent years, different strategies aiming patient outcomes incorporating immune checkpoint inhibitors in treatment paradigm were explored. Two key management approaches emerged: risk-adapted adjuvant immunotherapy universal perioperative immunotherapy-based We review rationale, current evidence, challenges, future directions muscle-invasive urothelial carcinoma.
Language: Английский
Citations
0